United Capital Financial Advisers, LLC Tyme Technologies, Inc. Transaction History

United Capital Financial Advisers, LLC

  • $11.5 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
BUY
$0.6 - $1.04 $14,770 - $25,601
24,617 New
24,617 $15,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track United Capital Financial Advisers, LLC Portfolio

Follow United Capital Financial Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on United Capital Financial Advisers, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email